Oncotarget

Research Papers:

Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies

Ye Li, Guanqiao Jin and Danke Su _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:35743-35749. https://doi.org/10.18632/oncotarget.16182

Metrics: PDF 1964 views  |   HTML 2293 views  |   ?  


Abstract

Ye Li1,2, Guanqiao Jin1, Danke Su1

1Department of Radiology, Cancer Hospital of Guangxi Medical University, Nanning, People’s Republic of China

2Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, People’s Republic of China

Correspondence to:

Danke Su, email: [email protected]

Keywords: lung cancer, brain metastases, magnetic resonance imaging, positron emission tomography, positron emission tomography/computed tomography

Received: February 13, 2017     Accepted: March 06, 2017     Published: March 14, 2017

ABSTRACT

Objective: We undertook this meta-analysis to compare the significance of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for diagnosing brain metastases of lung cancer patients.

Results: Five articles comprising 941 patients were included for analysis. The sensitivities with 95% confidence interval for PET/PET-CT and MRI were 0.21 (0.13 − 0.32) and 0.77 (95% CI = 0.60 − 0.89), specificities were 1.00 (0.99 − 1.00) and 0.99 (0.97 − 1.00), and the areas under curve were 0.98 (0.96 − 0.89) and 0.97 (0.96 − 0.98).

Materials and Methods: A computerized literature search of studies was conducted in the Pubmed and Embase databases. Meta-analysis methods were used to calculate the sensitivities, specificities, likelihood ratios ratios, diagnostic odd ratios, and areas under summary receiver operating characteristic curves for PET/PET-CT and MRI, respectively.

Conclusions: The analysis suggested Gadolinium-enhanced MRI had higher sensitivity than 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer. MRI may provide additional information to PET-CT for diagnosing brain metastatic lesions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16182